Story

Argen-X Stock Hits 52-Week High as UBS Cites $20 Billion Potential for Vyvgart

ENTHMSVIIDZHZH-TWJAKOHI
Aug 26, 20262 min read
Argen-X Stock Hits 52-Week High as UBS Cites $20 Billion Potential for Vyvgart
Text size
Background

Shares of Argen-X (ARGX) rose on August 26, continuing a rally fueled by a significant analyst upgrade. The stock gained 2.2% to trade at €898.6 after hitting a new 52-week high of €911.4 earlier in the session, with buying interest sustained by a bullish note from UBS.

UBS Upgrade Fuels Rally

In a note published the prior session, UBS upgraded Argen-X from a 'Neutral' to a 'Buy' rating and substantially increased its price target to €1,400 from a previous €960. The bank's conviction stems from the blockbuster potential of the company's flagship therapy, Vyvgart.

UBS analysts project that Vyvgart could achieve peak sales of approximately $20 billion. This optimistic forecast follows better-than-expected data from the Phase 3 ALKIVIA trial for the drug in treating autoimmune myositis. The bank described Argen-X as a rare and successful growth story in the biopharmaceutical industry.

Divergent Views on Wall Street

The bullish sentiment from UBS is not universally shared, creating a tug-of-war among analysts. While the upgrade is driving the current move, other banks have adopted a more cautious stance following the stock's recent appreciation of nearly 50% since its March lows.

Sample IUX Markets – In-articleAd
  • Deutsche Bank: Downgraded Argen-X to 'Hold' on August 25, citing the stock's strong recent performance.
  • Berenberg: Also shifted its rating to 'Hold', though it raised its price target to €925 from €900 to account for the positive myositis data.
  • Wells Fargo: Maintained its 'Overweight' rating and increased its price target on the company's American Depositary Receipts (ADRs) to $1,420.

A Company-Specific Move

The advance in Argen-X shares appears to be driven entirely by company-specific news, as the broader market is providing little support. Major U.S. indices like the S&P 500 and Nasdaq were trading slightly lower, and the Belgian BEL 20 index showed no significant momentum. No major economic data or central bank announcements were noted as influencing factors.

With the stock having more than tripled over the past five years and now trading near all-time highs, investors are weighing a compelling clinical and commercial growth story against a valuation that some analysts consider to be stretched.

Read next

More on Stocks
Back to latest news

LATEST